上海宏创医疗科技有限公司、江苏恒瑞医药集团有限公司通过 认购 Fortunatus Capital Fund I LP 份额分别收购 Ribogenics, Inc. 17.6%、 7.6%股权。Ribogenics, Inc.从事新药研发，通过自 身 RNA 剪接平台技术筛选高特异性与亲和力的小分子药物，用于治 疗包括癌症、自身免疫性疾病、神经退行性疾病、肝病、眼病及多 种罕见病等。
Yves Joseph Ribeill, Ph.D., founded SCYNEXIS, Inc (NASDAQ: SCYX) and served as President and CEO from 1999 to 2015. Dr. Ribeill has more than 35 years of experience in the healthcare industry, with an expertise in anti-infective diseases including bacterial, fungal, viral and parasiticidal and in microbiome-centric diseases. Prior to moving to the U.S. 23 years ago, Dr. Ribeill held several management positions during his international career with Rhône-Poulenc and Aventis in France and in the UK.Dr. Ribeill was a member of the Scientific Advisory Committee of the World Health Organization, the Medicines for Malaria Venture and is currently the CEO of Ribogenics, Inc., an early stage R&D company.
使用《赢家江恩软件》官方看图分析该股>>
老乌龟
恒瑞又一前沿布局海外投资RNA平台
上海宏创医疗科技有限公司、江苏恒瑞医药集团有限公司通过
认购 Fortunatus Capital Fund I LP 份额分别收购 Ribogenics,
Inc. 17.6%、 7.6%股权。Ribogenics, Inc.从事新药研发，通过自
身 RNA 剪接平台技术筛选高特异性与亲和力的小分子药物，用于治
疗包括癌症、自身免疫性疾病、神经退行性疾病、肝病、眼病及多
种罕见病等。
Yves Joseph Ribeill, Ph.D., founded SCYNEXIS, Inc (NASDAQ: SCYX) and served as President and CEO from 1999 to 2015. Dr. Ribeill has more than 35 years of experience in the healthcare industry, with an expertise in anti-infective diseases including bacterial, fungal, viral and parasiticidal and in microbiome-centric diseases. Prior to moving to the U.S. 23 years ago, Dr. Ribeill held several management positions during his international career with Rhône-Poulenc and Aventis in France and in the UK.Dr. Ribeill was a member of the Scientific Advisory Committee of the World Health Organization, the Medicines for Malaria Venture and is currently the CEO of Ribogenics, Inc., an early stage R&D company.
参考；
。
分享：
相关帖子